Skip to main content

Non-Small-Cell Lung

2
Pipeline Programs
5
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 3 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
CanakinumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT03626545Terminated245Est. Dec 2021
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-08046033Phase 11 trial
Active Trials
NCT07519655Recruiting250Est. Jul 2029
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in ChinaN/A1 trial
Active Trials
NCT07316062Not Yet Recruiting3,000Est. Apr 2029
Chia Tai TianQing Pharmaceutical Group
1 program
Anlotinib HydrochlorideN/A1 trial
Active Trials
NCT03766490Unknown66Est. Dec 2020
Roche
RocheSTAVANGER NORWAY, Norway
1 program
AtezolizumabPHASE_3Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
SandozCanakinumab
PfizerPF-08046033
AstraZenecaA Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Chia Tai TianQing Pharmaceutical GroupAnlotinib Hydrochloride

Clinical Trials (4)

Total enrollment: 3,561 patients across 4 trials

NCT03626545SandozCanakinumab

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

Start: Jan 2019Est. completion: Dec 2021245 patients
Phase 3Terminated
NCT07519655PfizerPF-08046033

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Start: Apr 2026Est. completion: Jul 2029250 patients
Phase 1Recruiting
NCT07316062AstraZenecaA Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

Start: Apr 2026Est. completion: Apr 20293,000 patients
N/ANot Yet Recruiting
NCT03766490Chia Tai TianQing Pharmaceutical GroupAnlotinib Hydrochloride

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Start: Mar 2019Est. completion: Dec 202066 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 3,561 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.